GB201801226D0 - Modulators of Rho-associated protein kinase - Google Patents
Modulators of Rho-associated protein kinaseInfo
- Publication number
- GB201801226D0 GB201801226D0 GBGB1801226.0A GB201801226A GB201801226D0 GB 201801226 D0 GB201801226 D0 GB 201801226D0 GB 201801226 A GB201801226 A GB 201801226A GB 201801226 D0 GB201801226 D0 GB 201801226D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- rho
- modulators
- protein kinase
- associated protein
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (29)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1801226.0A GB201801226D0 (en) | 2018-01-25 | 2018-01-25 | Modulators of Rho-associated protein kinase |
| BR112020013759-6A BR112020013759A2 (pt) | 2018-01-25 | 2019-01-25 | triazóis substituídos por heterociclilamino como moduladores de proteína cinase associada a rho |
| SI201930178T SI3743420T1 (sl) | 2018-01-25 | 2019-01-25 | Heterociklilamino substituirani triazoli kot modulatorji z RHO povezane protein kinaze |
| US16/964,904 US11497751B2 (en) | 2018-01-25 | 2019-01-25 | Modulators of Rho-associated protein kinase |
| EP19702694.1A EP3743420B1 (en) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
| LTEPPCT/GB2019/050215T LT3743420T (lt) | 2018-01-25 | 2019-01-25 | Heterociklilaminu pakeisti triazolai, kaip su rho susijusios proteinkinazės moduliatoriai |
| MX2020007898A MX2020007898A (es) | 2018-01-25 | 2019-01-25 | Moduladores de cinasa de proteina asociada con rho. |
| PCT/GB2019/050215 WO2019145729A1 (en) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
| HRP20220269TT HRP20220269T8 (hr) | 2018-01-25 | 2019-01-25 | Heterociklilamino-supstituirani triazoli kao modulatori rho-povezane protein kinaze |
| EP21214072.7A EP4026834A1 (en) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
| HUE19702694A HUE058940T2 (hu) | 2018-01-25 | 2019-01-25 | Heterociklilamino-szubsztituált triazolok mint a RHO-asszociált protein kináz modulátorai |
| SG11202006087UA SG11202006087UA (en) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
| CA3088330A CA3088330A1 (en) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
| JP2020561950A JP7518324B2 (ja) | 2018-01-25 | 2019-01-25 | Ｒｈｏ関連プロテインキナーゼのモジュレーター |
| EA202091711A EA202091711A1 (ru) | 2018-01-25 | 2019-01-25 | ГЕТЕРОЦИКЛИЛАМИНОЗАМЕЩЕННЫЕ ТРИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ |
| PT197026941T PT3743420T (pt) | 2018-01-25 | 2019-01-25 | Triazoles substituídos com heterociclilamino como moduladores da proteína-cinase associada à rho |
| ES19702694T ES2907833T3 (es) | 2018-01-25 | 2019-01-25 | Triazoles sustituidos con heterociclilamino como moduladores de proteína quinasa asociada a Rho |
| CN201980010083.3A CN111655681B (zh) | 2018-01-25 | 2019-01-25 | 杂环基氨基取代的三唑类化合物作为Rho相关蛋白激酶的调节剂 |
| AU2019213214A AU2019213214B2 (en) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituted triazoles as modulators of Rho-associated protein kinase |
| DK19702694.1T DK3743420T3 (da) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase |
| PL19702694T PL3743420T3 (pl) | 2018-01-25 | 2019-01-25 | Heterocykliloaminopodstawione triazole jako modulatory kinazy białkowej związanej z rho |
| KR1020207022578A KR20200113216A (ko) | 2018-01-25 | 2019-01-25 | Ｒｈｏ 관련 단백질 키나아제의 조절인자로서의 헤테로사이클릴아미노 치환 트리아졸 |
| PH12020550986A PH12020550986A1 (en) | 2018-01-25 | 2020-06-25 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
| ZA2020/03983A ZA202003983B (en) | 2018-01-25 | 2020-06-30 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
| IL275988A IL275988B2 (en) | 2018-01-25 | 2020-07-12 | Heterocyclamino-converted triazoles as modulators of rho-related protein kinase |
| CY20221100132T CY1125017T1 (el) | 2018-01-25 | 2022-02-16 | Ετεροκυκλυλαμινο-υποκατεστημενες τριαζολες ως ρυθμιστες της πρωτεϊνικης κινασης που σχετιζεται me rho |
| US17/896,626 US11878020B2 (en) | 2018-01-25 | 2022-08-26 | Modulators of Rho-associated protein kinase |
| JP2023200631A JP2024026193A (ja) | 2018-01-25 | 2023-11-28 | Ｒｈｏ関連プロテインキナーゼのモジュレーター |
| US18/534,285 US20240216386A1 (en) | 2018-01-25 | 2023-12-08 | Modulators of rho-associated protein kinase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1801226.0A GB201801226D0 (en) | 2018-01-25 | 2018-01-25 | Modulators of Rho-associated protein kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201801226D0 true GB201801226D0 (en) | 2018-03-14 |
Family
ID=61558335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1801226.0A Ceased GB201801226D0 (en) | 2018-01-25 | 2018-01-25 | Modulators of Rho-associated protein kinase |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11497751B2 (hr) |
| EP (2) | EP4026834A1 (hr) |
| JP (1) | JP2024026193A (hr) |
| KR (1) | KR20200113216A (hr) |
| CN (1) | CN111655681B (hr) |
| AU (1) | AU2019213214B2 (hr) |
| BR (1) | BR112020013759A2 (hr) |
| CA (1) | CA3088330A1 (hr) |
| CY (1) | CY1125017T1 (hr) |
| DK (1) | DK3743420T3 (hr) |
| EA (1) | EA202091711A1 (hr) |
| ES (1) | ES2907833T3 (hr) |
| GB (1) | GB201801226D0 (hr) |
| HR (1) | HRP20220269T8 (hr) |
| HU (1) | HUE058940T2 (hr) |
| IL (1) | IL275988B2 (hr) |
| LT (1) | LT3743420T (hr) |
| MX (1) | MX2020007898A (hr) |
| PH (1) | PH12020550986A1 (hr) |
| PL (1) | PL3743420T3 (hr) |
| PT (1) | PT3743420T (hr) |
| SG (1) | SG11202006087UA (hr) |
| SI (1) | SI3743420T1 (hr) |
| WO (1) | WO2019145729A1 (hr) |
| ZA (1) | ZA202003983B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
| CN111718310B (zh) * | 2019-08-19 | 2021-06-11 | 中国药科大学 | 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物 |
| CN110845410B (zh) * | 2019-10-29 | 2021-02-26 | 暨明医药科技（苏州）有限公司 | 一种一锅法制备6,7-二甲氧基-3,4-二氢异喹啉盐酸盐的方法 |
| WO2023009475A1 (en) * | 2021-07-26 | 2023-02-02 | President And Fellows Of Harvard College | Rock2 inhibitors and uses thereof |
| CN113999211B (zh) * | 2021-11-23 | 2022-11-29 | 郑州大学 | 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物 |
| GB202200735D0 (en) * | 2022-01-20 | 2022-03-09 | Redx Pharma Plc | Compounds |
| WO2023182856A1 (ko) * | 2022-03-24 | 2023-09-28 | 서울대학교산학협력단 | 로-키나제 억제제를 포함하는 켈로이드 등 피부 섬유화 질환의 예방 또는 치료용 약학적 조성물 및 그의 용도 |
| CN115124558A (zh) * | 2022-07-08 | 2022-09-30 | 闽都创新实验室 | 一种芳基硼酸酯类化合物的制备方法及其应用 |
| WO2024123129A1 (ko) * | 2022-12-08 | 2024-06-13 | 한국과학기술원 | 파브리병의 예방 또는 치료용 조성물 |
| CN116891460A (zh) * | 2023-07-12 | 2023-10-17 | 浙江大学 | 一种吲唑类衍生物或其药用盐及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9207396D0 (en) | 1992-04-03 | 1992-05-13 | Merck Sharp & Dohme | Therapeutic agents |
| HUP0302173A2 (hu) * | 2000-09-15 | 2003-09-29 | Vertex Pharmaceuticals Incorporated | Protein kináz inhibitorokként alkalmazható pirazolvegyületek |
| TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| WO2004052280A2 (en) * | 2002-12-10 | 2004-06-24 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
| US20050288347A1 (en) * | 2004-03-26 | 2005-12-29 | Hodge Carl N | Certain triazole-based compounds, compositions, and uses thereof |
| WO2006135383A2 (en) * | 2004-08-04 | 2006-12-21 | Myriad Genetics, Inc. | Indazoles |
| AU2007267859B2 (en) | 2006-05-25 | 2012-04-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
| DE102007022565A1 (de) * | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| US8344144B2 (en) * | 2008-06-18 | 2013-01-01 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| RU2018100142A (ru) * | 2010-03-24 | 2019-02-20 | Амитек Терапетикс Солюшинс, Инк. | Гетероциклические соединения, эффективные для ингибирования киназы |
| WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012084704A1 (en) | 2010-12-20 | 2012-06-28 | Merck Serono S.A. | Indazolyl triazole derivatives as irak inhibitors |
| EP3262041A4 (en) * | 2015-02-27 | 2018-08-01 | Lycera Corporation | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
| PE20220502A1 (es) | 2015-12-16 | 2022-04-07 | Loxo Oncology Inc | Compuestos utiles como inhibidores de cinasa |
| KR102469161B1 (ko) * | 2017-06-30 | 2022-11-23 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도 |
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
-
2018
- 2018-01-25 GB GBGB1801226.0A patent/GB201801226D0/en not_active Ceased
-
2019
- 2019-01-25 CN CN201980010083.3A patent/CN111655681B/zh active Active
- 2019-01-25 PL PL19702694T patent/PL3743420T3/pl unknown
- 2019-01-25 EA EA202091711A patent/EA202091711A1/ru unknown
- 2019-01-25 HU HUE19702694A patent/HUE058940T2/hu unknown
- 2019-01-25 CA CA3088330A patent/CA3088330A1/en active Pending
- 2019-01-25 ES ES19702694T patent/ES2907833T3/es active Active
- 2019-01-25 WO PCT/GB2019/050215 patent/WO2019145729A1/en active Application Filing
- 2019-01-25 AU AU2019213214A patent/AU2019213214B2/en active Active
- 2019-01-25 DK DK19702694.1T patent/DK3743420T3/da active
- 2019-01-25 SG SG11202006087UA patent/SG11202006087UA/en unknown
- 2019-01-25 US US16/964,904 patent/US11497751B2/en active Active
- 2019-01-25 LT LTEPPCT/GB2019/050215T patent/LT3743420T/lt unknown
- 2019-01-25 KR KR1020207022578A patent/KR20200113216A/ko not_active Application Discontinuation
- 2019-01-25 MX MX2020007898A patent/MX2020007898A/es unknown
- 2019-01-25 BR BR112020013759-6A patent/BR112020013759A2/pt unknown
- 2019-01-25 HR HRP20220269TT patent/HRP20220269T8/hr unknown
- 2019-01-25 EP EP21214072.7A patent/EP4026834A1/en active Pending
- 2019-01-25 SI SI201930178T patent/SI3743420T1/sl unknown
- 2019-01-25 EP EP19702694.1A patent/EP3743420B1/en active Active
- 2019-01-25 PT PT197026941T patent/PT3743420T/pt unknown
-
2020
- 2020-06-25 PH PH12020550986A patent/PH12020550986A1/en unknown
- 2020-06-30 ZA ZA2020/03983A patent/ZA202003983B/en unknown
- 2020-07-12 IL IL275988A patent/IL275988B2/en unknown
-
2022
- 2022-02-16 CY CY20221100132T patent/CY1125017T1/el unknown
- 2022-08-26 US US17/896,626 patent/US11878020B2/en active Active
-
2023
- 2023-11-28 JP JP2023200631A patent/JP2024026193A/ja active Pending
- 2023-12-08 US US18/534,285 patent/US20240216386A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201801226D0 (en) | Modulators of Rho-associated protein kinase | |
| IL287136A (en) | Receptor inhibitors - interacting with protein kinase 1 | |
| IL275333B1 (en) | Inhibitors of fibroblast activation protein | |
| IL282179A (en) | Protein tyrosine phosphatase inhibitors | |
| EP3423451A4 (en) | INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN | |
| GB201706477D0 (en) | Modification of polypeptides | |
| EP3177295A4 (en) | Uses of salt-inducible kinase (sik) inhibitors | |
| EP3423437A4 (en) | INHIBITORS OF THE LINK BETWEEN THE WDR5 PROTEIN AND ITS LIAISON PARTNERS | |
| IL281492A (en) | Modulators of PNPLA3 expression | |
| IL304110A (en) | Keap1–nrf2 protein–protein interaction inhibitors | |
| EP3679031A4 (en) | PROTEIN WDR5-PROTEIN INHIBITORS | |
| IL283967A (en) | Modulators of hsd17b13 expression | |
| ZA201808238B (en) | Certain protein kinase inhibitors | |
| EP3555092A4 (en) | PROTEIN KINASE INHIBITORS | |
| EP3134390A4 (en) | Small molecule inhibitors of g protein coupled receptor 6 kinase polypeptides | |
| IL276007A (en) | Modulators for dnm2 expression | |
| EP3641761A4 (en) | ALPHA-SYNUCLEIN MODULATORS | |
| EP3134399A4 (en) | Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides | |
| GB201700484D0 (en) | Modulators of Rho-associated protein kinase | |
| GB201700490D0 (en) | Modulators of rho-associated protein kinase | |
| GB201713559D0 (en) | Modification of polypeptides | |
| EP3250687A4 (en) | Modulators of protein tyrosine phosphatase and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |